This week on the Policy and Medicine Podcast, we unpack a range of timely and impactful stories that highlight critical changes and discussions in healthcare policy and regulation. Available on Spotify and other podcast platforms, tune in to hear our expert analysis and insights. Here’s a snapshot of the stories covered in this episode:
Minnesota’s 340B Program Report Sparks Call for Reforms
A recently released report from Minnesota exposes potential abuses within the state’s 340B Drug Pricing Program. The findings have reignited calls for greater oversight and reform to ensure the program fulfills its original mission of helping underserved populations. The podcast delves into the key takeaways from the report and the implications for other states and stakeholders involved in 340B.
Read the full article: Minnesota’s 340B Program Report
Bipartisan Legislation to Avoid Medicare Reimbursement Cuts
Congress is once again stepping in to address looming cuts to Medicare reimbursement rates. Bipartisan legislation has been introduced to stabilize payments, ensuring healthcare providers aren’t faced with financial uncertainty in the coming year. This episode breaks down the proposed legislation, its potential impact on physicians, and the broader implications for Medicare beneficiaries.
Read the full article: Bipartisan Legislation for Medicare Reimbursement
Navigating SAMHSA’s New Guidelines for Opioid Treatment Programs
The Substance Abuse and Mental Health Services Administration (SAMHSA) has released updated federal guidelines for opioid treatment programs. These new guidelines aim to expand access to treatment and improve care delivery amidst the ongoing opioid crisis. In the podcast, we analyze what these changes mean for providers, patients, and policymakers.
Read the full article: SAMHSA’s New Federal Guidelines
FDA’s New Reports on Communication and Guidance Practices
The FDA has issued two new reports outlining best practices for communication and guidance document development. These reports are part of the agency’s broader effort to improve transparency and engagement with stakeholders. Our discussion focuses on the recommendations, potential challenges, and how these changes might influence future FDA actions.
Read the full article: FDA Reports on Best Practices
Fifth Circuit Decision on No Surprises Act Guidance
The Fifth Circuit Court of Appeals has affirmed a lower court’s decision to vacate certain guidance under the No Surprises Act. This ruling could significantly impact how the Act is implemented, particularly around payment disputes between providers and insurers. The podcast explores the details of the decision and its potential ripple effects across the healthcare landscape.
Read the full article: Fifth Circuit Decision on No Surprises Act
Don’t miss this in-depth analysis of these critical stories on the Policy and Medicine Podcast. Subscribe and listen today on Spotify and other podcast platforms for weekly updates and expert commentary on the ever-evolving world of healthcare policy and medicine.